Jump to content

Protein-bound paclitaxel

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Boghog (talk | contribs) at 11:35, 24 October 2023 (consistent citation formatting). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Protein-bound paclitaxel
Combination of
PaclitaxelMitotic inhibitor
AlbuminDelivery vehicle
Clinical data
Trade namesAbraxane, others
AHFS/Drugs.comMonograph
MedlinePlusa619008
License data
Pregnancy
category
  • AU: D
Routes of
administration		Intravenous (IV)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.[1][2][3] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.[4] It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".[5]

This treatment was approved in the United States in 2005,[6] and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[7][8] In 2012, the FDA widened the approved uses to include treatment for NSCLC.[2][9] In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.[3]

Society and culture

Abraxane is registered on the Australian Register of Therapeutic Goods for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy.[10] Abraxane is also included on the Schedule of the Australian Pharmaceutical Benefits Scheme although[11] the manufacturer was unable to convince the independent Pharmaceutical Benefits Advisory Committee that the drug warranted a higher price than existing comparator drugs. [12] Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform.[13]

In 2010, Abraxis was acquired by Celgene, which now markets Abraxane.[14] Total revenue from the sales of Abraxane for 2009 were $314.5 million.[15] In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer.[16] In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase.[17]

The British National Institute for Health and Care Excellence (NICE) announced in 2015, that it would not support the routine use of protein-bound paclitaxel in advanced pancreatic cancer on the NHS.[18]

References

  1. ^ "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. February 2, 2011.
  2. ^ a b "FDA approves Celgene's Abraxane for lung cancer". Reuters. October 12, 2012.
  3. ^ a b Pollack A (7 September 2013). "F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer". New York Times. Retrieved 6 September 2013.
  4. ^ "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. 2006.
  5. ^ "Abraxane". Orpha Net. 6 September 2013. Retrieved 20 July 2015.
  6. ^ Knapp A (27 August 2020). "The Inside Story Of Biotech's Barnum And His Covid Cures". Forbes. Retrieved 27 August 2020.
  7. ^ "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. 2006.
  8. ^ "Abraxane EPAR". European Medicines Agency (EMA). 9 March 2020. Retrieved 9 March 2020.
  9. ^ "Paclitaxel (Abraxane)". U.S. Food and Drug Administration. 11 October 2012. Retrieved 10 December 2012.
  10. ^ "Resolution 9190". Therapeutic Goods Administration (Tga). 6 June 2008.
  11. ^ Vines T, Faunce T (May 2009). "Assessing the safety and cost-effectiveness of early nanodrugs". Journal of Law and Medicine. 16 (5): 822–845. PMID 19554862.
  12. ^ "PBAC, Public Summary Document". health.gov.au. November 2008.
  13. ^ "Celgene: A Global Biopharmaceutical Company Committed to Improving the Lives of Patients Worldwide with Innovative and Life-Changing Treatments". www.abraxisbio.com.
  14. ^ "Celgene Completes Acquisition of Abraxis". Celgene (Press release).
  15. ^ "Abraxis Reports Phase III Success with Abraxane in First-Line NSCLC". www.genengnews.com/. 2010.
  16. ^ "FDA approves Abraxane for late-stage pancreatic cancer". FDA (Press release).
  17. ^ "Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results (NASDAQ:CELG)". Celgene (Press release).
  18. ^ "NHS England stop access to Abraxane - Pancreatic Cancer UK". www.pancreaticcancer.org.uk/. September 2015.

Further reading

  • "Human albumin". Drug Information Portal. U.S. National Library of Medicine.
  • "Paclitaxel". Drug Information Portal. U.S. National Library of Medicine.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Protein-bound_paclitaxel&oldid=1181651454"